New York, USA, May 08, 2025 (GLOBE NEWSWIRE) — High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020\u20132034) | DelveInsight\u00a0<\/strong><\/p>\n As per DelveInsight\u2019s estimates, among the 7MM, the US captured the highest market of high- and low-grade serous ovarian cancer of nearly USD 1,900 million in 2024, which is expected to increase due to the launch of emerging therapies.<\/em><\/strong><\/p>\n DelveInsight\u2019s Ovarian Cancer Market Insights<\/strong><\/a> report includes a comprehensive understanding of current treatment practices, emerging ovarian cancer drugs, market share of individual therapies, and current and forecasted ovarian cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n Key Takeaways from the Ovarian Cancer Market Report<\/strong><\/p>\n Discover which therapies are expected to grab the ovarian cancer market share @ Ovarian Cancer Market <\/strong>Report<\/strong><\/a><\/p>\n Ovarian Cancer Overview<\/strong><\/p>\n Ovarian cancer is associated with a high mortality rate and ranks as the fifth leading cause of cancer-related deaths among women globally. Although its exact cause remains unknown, lifestyle factors such as smoking, obesity, and poor dietary habits may contribute to the risk. A strong family history of breast or ovarian cancer significantly elevates susceptibility, particularly in individuals with BRCA1 or BRCA2 gene mutations.<\/p>\n Histologically, ovarian cancer is primarily epithelial in nature and is classified into five main subtypes: serous, clear cell, endometrioid, mucinous, and unspecified. These are further grouped into Type I and Type II tumors. Type I tumors, often linked to atypical proliferative lesions, are usually detected early and have a more favorable prognosis. In contrast, Type II tumors\u2014such as high-grade serous ovarian carcinoma (HGSOC), carcinosarcoma, and undifferentiated carcinoma\u2014are typically aggressive, high-grade malignancies believed to arise from serous tubal intraepithelial carcinoma. These are usually diagnosed at advanced FIGO stages and carry a poor prognosis.<\/p>\n Early detection of ovarian cancer is challenging due to the absence of specific symptoms in its initial stages. Nonetheless, persistent signs such as abdominal bloating, early satiety, frequent urination, pelvic or abdominal pain, digestive disturbances, irregular menstruation, fatigue, painful intercourse, and unexplained weight changes should prompt clinical evaluation, as they may signal the presence of the disease.<\/p>\n Ovarian Cancer Epidemiology Segmentation<\/strong><\/p>\n The ovarian cancer epidemiology section provides insights into the historical and current ovarian cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The ovarian cancer market report<\/strong><\/a> proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n Download the report to understand which factors are driving ovarian cancer epidemiology trends @ Ovarian Cancer Epidemiological Insights<\/strong><\/a><\/p>\n Ovarian Cancer Treatment Market\u00a0<\/strong><\/p>\n Treatment strategies for ovarian cancer are typically tailored based on the cancer type, stage, and individual patient factors. Most patients undergo surgery to remove the tumor, but additional therapies may be necessary either before, after, or both before and after surgery. Standard treatment often includes a combination of surgery, chemotherapy, and targeted therapy.<\/p>\n For newly diagnosed ovarian cancer, the most effective drugs are platinum-based agents such as cisplatin or carboplatin, usually paired with a taxane like paclitaxel or docetaxel. Initial treatment often involves primary cytoreductive surgery (aimed at reducing tumor burden), followed by platinum-based chemotherapy. Alternatively, some patients may receive chemotherapy first (neoadjuvant therapy), followed by interval cytoreductive surgery and further chemotherapy.<\/p>\n However, the optimal first-line approach for low-grade serous ovarian carcinomas (LGSOCs) remains unclear. Some newly diagnosed patients may undergo chemotherapy followed by maintenance hormonal therapy, while others may receive hormonal therapy alone. Data from the National Cancer Database suggest that roughly 20% of patients with advanced-stage LGSOC do not receive adjuvant chemotherapy.<\/p>\n A major challenge for women with advanced-stage ovarian cancer is the high rate of recurrence after initial platinum-based chemotherapy. In addition, many patients eventually develop resistance to these treatments. Despite this, recent developments in therapies for recurrent ovarian cancer\u2014such as angiogenesis inhibitors, PARP inhibitors, and immunotherapy\u2014have shown promising outcomes. Although the role of PARP inhibitors in both newly diagnosed and recurrent cases is still under investigation, early results have been encouraging.<\/p>\n Learn more about the market of ovarian cancer @ Ovarian Cancer <\/strong>Treatment<\/strong><\/a>\u00a0<\/strong><\/p>\n Ovarian Cancer Emerging Drugs and Companies<\/strong><\/p>\n Some of the drugs in the pipeline include Avutometinib + defactinib<\/strong> (Verastem Oncology), Relacorilant<\/strong> (Corcept Therapeutics), Sacituzumab Tirumotecan<\/strong> (Merck and Kelun-Biotech), IMFINZI <\/strong>(AstraZeneca), Rinatabart sesutecan <\/strong>(Genmab), Nemvaleukin alfa <\/strong>(Mural Oncology), and others.\u00a0<\/p>\n Avutometinib <\/strong>is a RAF\/MEK Clamp that forms inactive complexes with ARAF, BRAF, and CRAF, leading to comprehensive and sustained inhibition of the RAS pathway. This mechanism is designed to deliver a more robust and durable anti-tumor effect.<\/p>\n According to Verastem\u2019s 2025 corporate presentation, the company plans to present further analyses from the RAMP 201 trial at a medical conference in Q1 2025, publish the primary results from the full RAMP 201 dataset, complete patient enrollment in the Phase III confirmatory RAMP 301 trial by year-end 2025, and share initial findings from the RAMP 201J Phase II study in Japan during the second half of 2025.<\/p>\n In December 2024, the FDA accepted and granted Priority Review for the New Drug Application (NDA) seeking approval of avutometinib in combination with defactinib for adult patients with recurrent low-grade serous ovarian cancer (LGSOC) who have received at least one prior systemic treatment and carry a KRAS mutation. The target action date under the Prescription Drug User Fee Act (PDUFA) is June 30, 2025.<\/p>\n Relacorilant <\/strong>is a selective cortisol modulator that specifically targets the glucocorticoid receptor (GR) without interacting with other hormone receptors in the body. Corcept Therapeutics is evaluating relacorilant across several serious conditions, including ovarian, adrenal, and prostate cancers, as well as Cushing\u2019s syndrome. According to the company\u2019s 2025 presentation, results from the Phase III ROSELLA trial are expected in the first quarter of 2025.<\/p>\n Sac-TMT<\/strong> is an experimental ADC composed of three key elements: 1) sacituzumab, a monoclonal antibody that targets TROP2, 2) a cytotoxic agent from the topoisomerase 1 inhibitor class, and 3) a novel, hydrolyzable yet irreversible linker that connects the antibody to the payload using proprietary conjugation technology. The therapy is currently being evaluated in a Phase III clinical trial for platinum-sensitive recurrent ovarian cancer.<\/p>\n The other pipeline therapies for ovarian cancer include\u00a0<\/p>\n The anticipated launch of these emerging therapies are poised to transform the ovarian cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the ovarian cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about ovarian cancer clinical trials, visit @ Ovarian Cancer Treatment Drugs<\/strong><\/a>\u00a0<\/strong><\/p>\n Ovarian Cancer Market Dynamics<\/strong><\/a><\/p>\n The ovarian cancer market dynamics are anticipated to change in the coming years. PARP inhibitors<\/strong> have become a cornerstone in ovarian cancer maintenance therapy, particularly in first-line (1L) and recurrent settings<\/strong>, offering substantial clinical benefits for patients with BRCA mutations and homologous recombination deficiency (HRD)-positive tumors. The recent approval of ELAHERE<\/strong>\u2014the first ADC for ovarian cancer\u2014has paved the way for further innovation, encouraging key players like Sutro Biopharma, ProfoundBio\/Genmab, and Daiichi Sankyo\/Merck to accelerate their ADC development programs in this space.<\/p>\n Additionally, investigational agents like CBX-12<\/strong> show promise in broadening treatment options, especially for patients who are ineligible for antigen-targeted therapies such as monoclonal antibodies and ADCs<\/strong>. CBX-12 also holds potential for use in combination regimens with other anti-cancer agents, including immunotherapies, potentially enhancing treatment efficacy and expanding its clinical utility.<\/p>\n While many companies are focusing on platinum-resistant ovarian cancer (PROC)<\/strong>, a significant untapped opportunity exists in targeting platinum-sensitive ovarian cancer. With more than 50% of second-line (2L) patients<\/strong> falling into this category, effective non-chemotherapy alternatives could fulfill a critical need and reshape the treatment landscape in this underserved population.<\/p>\n Furthermore, many potential therapies are being investigated for the treatment of ovarian cancer, and it is safe to predict that the treatment space will significantly impact the ovarian cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies<\/strong> with improved efficacy and a further improvement in the diagnosis rate<\/strong> is expected to drive the growth of the ovarian cancer market in the 7MM.<\/p>\n However, several factors may impede the growth of the ovarian cancer market. Despite initial responsiveness to platinum-based therapies, a significant challenge in advanced ovarian cancer is the high relapse rate<\/strong>\u2014approximately 70\u201380% of patients<\/strong> eventually develop platinum-resistant disease, drastically narrowing the range of effective treatment options. While PARP inhibitors have played a pivotal role in extending survival, concerns over long-term hematologic toxicities<\/strong>, such as myelodysplastic syndrome and acute myeloid leukemia, have dampened enthusiasm for their use in homologous recombination proficient (HRP) patients.<\/p>\n Meanwhile, the emergence of next-generation ADCs such as Luveltamab tazevibulin and Rinatabart sesutecan<\/strong> is reshaping the treatment landscape. These agents, targeting PROC in the second-line (2L) and later settings, pose direct competition to ELAHERE<\/strong>. With the potential for use in earlier lines of therapy, they may challenge ELAHERE\u2019s market share by offering expanded utility and differentiated clinical benefits<\/strong>.<\/p>\n However, access to these novel therapies<\/strong> remains a key hurdle. Limited insurance coverage<\/strong>, especially in cost-sensitive regions, could significantly restrict patient access and slow the adoption of new treatments<\/strong>, underscoring the need for pricing strategies and value-based care models that ensure broader accessibility.<\/p>\n Moreover, ovarian cancer treatment poses a significant economic burden<\/strong> and disrupts patients\u2019 overall well-being and QOL. Furthermore, the ovarian cancer market growth may be offset by failures and discontinuation of emerging therapies<\/strong>, unaffordable pricing<\/strong>, market access and reimbursement issues<\/strong>, and a shortage of healthcare specialists<\/strong>. In addition, the undiagnosed, unreported cases and the unawareness<\/strong> about the disease may also impact the ovarian cancer market growth.<\/p>\n\n
![](\"https:\/\/ml.globenewswire.com\/Resource\/Download\/a25fe95f-0b8d-4807-a5b0-510b598ad68b\/ovarian-cancer-market.jpg\" "\\"Ovarian-Cancer-Market.jpg\\"")
<\/p>\n\n
\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/OGZiYmZmZDctYzA2My00Mzg4LThmMGUtYmRmZTE2MDZmYTM4LTEyMDQ5MzgtMjAyNS0wNS0wOC1lbg==\/tiny\/DelveInsight-Business-Research.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"